SIGA TECHNOLOGIES INC

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on medical countermeasures against biological threats. Its primary product is TPOXX, an antiviral medication available in oral and intravenous formulations for treating human smallpox disease caused by the variola virus. Outside the United States, oral formulations have also obtained regulatory clearances for smallpox, monkeypox, cowpox, and complications related to smallpox vaccination. The company sells its therapies primarily to governmental public health and defense agencies, including the United States Government through the Strategic National Stockpile and Department of Defense, as well as foreign governments and government-affiliated entities, occasionally utilizing distributor arrangements for international markets.

The company operates without internal manufacturing infrastructure, relying instead on third-party contract manufacturing organizations while maintaining a domestic United States supply chain. SIGA employs 49 full-time workers and conducts commercial operations spanning domestic and multiple international jurisdictions, including North America, Europe, and Asia, with its primary corporate offices located in the United States.

Summary of the business section of Siga Technologies's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 13, 2026, we had 49 full-time employees.”